ID

26219

Descripción

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00684216

Link

https://clinicaltrials.gov/show/NCT00684216

Palabras clave

Versiones (1)
  1. 11/10/17 11/10/17 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

11 de octubre de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Cancer NCT00684216

Inglés

Eligibility Breast Cancer NCT00684216

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. written informed consent.
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
2. proven infiltrating breast cancer with distant metastases or inoperable locally advanced disease.
Descripción

Invasive carcinoma of breast Distant metastasis | Disease Advanced Locally Inoperable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0853879
UMLS CUI [1,2]
C1269798
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0205179
UMLS CUI [2,3]
C1517927
UMLS CUI [2,4]
C0205187
3. positive estrogen receptor (≥ 10% positive nuclei at immunohistochemistry). progesterone and her-2 neu receptor have to be known.
Descripción

Estrogen receptor positive | Nuclei Percentage Positive Immunohistochemistry | Progesterone Known | erbB-2 Receptor Known

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0279754
UMLS CUI [2,1]
C0007610
UMLS CUI [2,2]
C0439165
UMLS CUI [2,3]
C1514241
UMLS CUI [2,4]
C0021044
UMLS CUI [3,1]
C0033308
UMLS CUI [3,2]
C0205309
UMLS CUI [4,1]
C0069515
UMLS CUI [4,2]
C0205309
4. - progressive disease during first line hormonal therapy (either tamoxifen or aromatase inhibitor) for metastatic or inoperable locally advanced disease. simultaneous use of lh-rh analogs is allowed. or - recurrence of disease (m1) during adjuvant hormonal therapy (either tamoxifen or aromatase inhibitor).
Descripción

Progressive Disease | First line Hormone Therapy | Tamoxifen | Aromatase Inhibitors | Neoplasm Metastasis | Disease Advanced Locally Inoperable | LH-RH Agonist allowed | Recurrent disease | Hormone Therapy Adjuvant

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1335499
UMLS CUI [2,1]
C1708063
UMLS CUI [2,2]
C0279025
UMLS CUI [3]
C0039286
UMLS CUI [4]
C0593802
UMLS CUI [5]
C0027627
UMLS CUI [6,1]
C0012634
UMLS CUI [6,2]
C0205179
UMLS CUI [6,3]
C1517927
UMLS CUI [6,4]
C0205187
UMLS CUI [7,1]
C1518041
UMLS CUI [7,2]
C0683607
UMLS CUI [8]
C0277556
UMLS CUI [9,1]
C0279025
UMLS CUI [9,2]
C1522673
5. no prior chemotherapy for metastatic disease
Descripción

Prior Chemotherapy Absent Neoplasm Metastasis

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0027627
6. willing and able to participate in quality of life investigation -
Descripción

Participation Quality of life Investigation

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0679823
UMLS CUI [1,2]
C0034380
UMLS CUI [1,3]
C1261322
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. other malignancy except carcinoma in situ, unless the other malignancy was treated 5 or more years ago with curative intent without the use of chemotherapy or radiation therapy.
Descripción

Malignant Neoplasms | Exception Carcinoma in Situ | Exception Curative procedure Malignant Neoplasms | Chemotherapy Absent | Therapeutic radiology procedure Absent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007099
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1276305
UMLS CUI [3,3]
C0006826
UMLS CUI [4,1]
C0392920
UMLS CUI [4,2]
C0332197
UMLS CUI [5,1]
C1522449
UMLS CUI [5,2]
C0332197
2. pregnancy or breast feeding women.
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
3. contra-indications to the use of capecitabine
Descripción

Medical contraindication capecitabine

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0671970
4. known cns metastases
Descripción

CNS metastases

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0686377
Volver a la parte superior de la página

Similar models

Eligibility Breast Cancer NCT00684216

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. written informed consent.
boolean
C0021430 (UMLS CUI [1])
Invasive carcinoma of breast Distant metastasis | Disease Advanced Locally Inoperable
Item
2. proven infiltrating breast cancer with distant metastases or inoperable locally advanced disease.
boolean
C0853879 (UMLS CUI [1,1])
C1269798 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1517927 (UMLS CUI [2,3])
C0205187 (UMLS CUI [2,4])
Estrogen receptor positive | Nuclei Percentage Positive Immunohistochemistry | Progesterone Known | erbB-2 Receptor Known
Item
3. positive estrogen receptor (≥ 10% positive nuclei at immunohistochemistry). progesterone and her-2 neu receptor have to be known.
boolean
C0279754 (UMLS CUI [1])
C0007610 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C1514241 (UMLS CUI [2,3])
C0021044 (UMLS CUI [2,4])
C0033308 (UMLS CUI [3,1])
C0205309 (UMLS CUI [3,2])
C0069515 (UMLS CUI [4,1])
C0205309 (UMLS CUI [4,2])
Progressive Disease | First line Hormone Therapy | Tamoxifen | Aromatase Inhibitors | Neoplasm Metastasis | Disease Advanced Locally Inoperable | LH-RH Agonist allowed | Recurrent disease | Hormone Therapy Adjuvant
Item
4. - progressive disease during first line hormonal therapy (either tamoxifen or aromatase inhibitor) for metastatic or inoperable locally advanced disease. simultaneous use of lh-rh analogs is allowed. or - recurrence of disease (m1) during adjuvant hormonal therapy (either tamoxifen or aromatase inhibitor).
boolean
C1335499 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C0279025 (UMLS CUI [2,2])
C0039286 (UMLS CUI [3])
C0593802 (UMLS CUI [4])
C0027627 (UMLS CUI [5])
C0012634 (UMLS CUI [6,1])
C0205179 (UMLS CUI [6,2])
C1517927 (UMLS CUI [6,3])
C0205187 (UMLS CUI [6,4])
C1518041 (UMLS CUI [7,1])
C0683607 (UMLS CUI [7,2])
C0277556 (UMLS CUI [8])
C0279025 (UMLS CUI [9,1])
C1522673 (UMLS CUI [9,2])
Prior Chemotherapy Absent Neoplasm Metastasis
Item
5. no prior chemotherapy for metastatic disease
boolean
C1514457 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
Participation Quality of life Investigation
Item
6. willing and able to participate in quality of life investigation -
boolean
C0679823 (UMLS CUI [1,1])
C0034380 (UMLS CUI [1,2])
C1261322 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Malignant Neoplasms | Exception Carcinoma in Situ | Exception Curative procedure Malignant Neoplasms | Chemotherapy Absent | Therapeutic radiology procedure Absent
Item
1. other malignancy except carcinoma in situ, unless the other malignancy was treated 5 or more years ago with curative intent without the use of chemotherapy or radiation therapy.
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007099 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1276305 (UMLS CUI [3,2])
C0006826 (UMLS CUI [3,3])
C0392920 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C1522449 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
Pregnancy | Breast Feeding
Item
2. pregnancy or breast feeding women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Medical contraindication capecitabine
Item
3. contra-indications to the use of capecitabine
boolean
C1301624 (UMLS CUI [1,1])
C0671970 (UMLS CUI [1,2])
CNS metastases
Item
4. known cns metastases
boolean
C0686377 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial